Logo Image
News|Articles|April 22, 2026

Nipocalimab Demonstrates Sustained Disease Control Over Two Years in Generalized Myasthenia Gravis

Listen
0:00 / 0:00

Key Takeaways

  • Vivacity-MG3 OLE data support durability of nipocalimab benefit across seropositive gMG subtypes, extending efficacy signals beyond the 24-week double-blind period to 120 weeks.
  • Week-96 outcomes showed persistent functional and strength improvements, with mean MG-ADL decreasing 6.47 points and QMG decreasing 5.97 points, consistent with sustained disease control.
SHOW MORE

Johnson & Johnson reported that nipocalimab (Imaavy) demonstrated sustained disease control and reductions in pathogenic IgG levels through more than two years in patients with generalized myasthenia gravis. Patients who achieved sustained minimal symptom expression showed greater quality-of-life improvements, while a new head-to-head trial comparing nipocalimab with another FcRn inhibitor is now underway.

New long-term data from Johnson & Johnson highlight sustained efficacy and disease control with nipocalimab (Imaavy) in adults with antibody-positive generalized myasthenia gravis (gMG),1 reinforcing the therapy’s potential as a durable treatment option in this chronic autoimmune condition.

Findings from the Phase 3 Vivacity-MG3 study2 and its ongoing open-label extension (OLE) demonstrate that nipocalimab maintained clinical benefits through 120 weeks of follow-up in a broad population of patients, including those who are anti-acetylcholine receptor–positive and anti–muscle-specific kinase–positive. The results were presented as part of multiple abstracts at the American Academy of Neurology Annual Meeting 2026.

Long-Term Efficacy and Disease Control

Sustained disease control remains a central goal in the management of gMG, where long-term symptom stability can reduce exacerbations and improve functional outcomes. According to investigators, the extended data build on earlier pivotal results by demonstrating that improvements can be maintained over time.

During the OLE phase, which followed the initial 24-week double-blind portion

Investigators note that these findings underscore the importance of durability in treatment response, particularly in a chronic disease such as gMG, where fluctuations in symptom severity can significantly impact daily functioning.

of the study, patients receiving nipocalimab showed continued reductions in disease severity. At 96 weeks, mean improvements included a 6.47-point reduction in Myasthenia Gravis Activities of Daily Living scores and a 5.97-point reduction in Quantitative Myasthenia Gravis scores, both standard measures of symptom burden and muscle strength.

Immunological Impact and Steroid Reduction

In addition to clinical efficacy, treatment was associated with a reduction of more than 64% in total immunoglobulin G (IgG), including pathogenic autoantibodies that drive disease progression. Corticosteroid use also declined over time, with more than half of patients reaching lower daily doses, reflecting a potential reduction in treatment burden.

A post-hoc analysis of the double-blind phase further examined minimal symptom expression (MSE), an emerging patient-centered endpoint defined by very low symptom levels sustained over time. Patients treated with nipocalimab plus standard of care were four times more likely to achieve sustained MSE compared with those receiving placebo.

Importantly, individuals who maintained this level of symptom control experienced greater improvements in quality of life, as measured by the Myasthenia Gravis Quality of Life 15-Item Scale Revised, compared with patients whose symptom improvements were not sustained.

Investigators note that these findings underscore the importance of durability in treatment response, particularly in a chronic disease such as gMG, where fluctuations in symptom severity can significantly impact daily functioning.

Ongoing Development and Head-to-Head Study

In parallel with these data, Johnson & Johnson has initiated a new clinical study, EPIC, designed to compare nipocalimab directly with another FcRn-blocking therapy in patients who have not previously received this class of treatment. The head-to-head trial is currently enrolling participants and is expected to provide further insight into comparative efficacy within the FcRn inhibitor class.

Collectively, the results from Vivacity-MG3 and its extension study contribute to a growing body of evidence supporting FcRn-targeted therapies as a mechanism for reducing pathogenic antibodies and achieving sustained disease control in gMG.

References

1. IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG). (2026 Apr 22). PR Newswire. https://prnmedia.prnewswire.com/news-releases/imaavy-nipocalimab-aahu-shows-over-two-years-of-sustained-disease-control-in-a-broad-population-with-generalized-myasthenia-gravis-gmg-302749496.html

2. Antozzi, C., Vu, T., Ramchandren, S., Nowak, R. J., et al. (2025 Feb 24). Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. National Library of Medicine. PubMed. https://pubmed.ncbi.nlm.nih.gov/39862879/

Related Content